Intended for healthcare professionals

PBC – how do you make the case for biologicals?

Ronald G Pate
The National Institute for Health and Clinical Excellence (NICE) technology appraisal guidance 103, Etanercept and efalizumab for the treatment of adults with psoriasis, was issued in July 2006. It recommends that etanercept (Enbrel®, Wyeth, UK) be used within its licensed indications in patients with severe plaque psoriasis when other treatments have not worked or the patient is intolerant to or has a contraindication to these treatments. A definition is given in the guidance of severe psoriasis but no definition is provided for what is meant by ‘intolerant to’.
Dermatology in practice 2006; 14(3): 14–16
To continue reading this article, please sign in or register.

Dermatology in practice was previously supported by Wyeth from 2008 to 2010, by Wyeth and Serono in 2007, by Wyeth and Shire from 2005 to 2006, by Medlock Medical in 2004 and by SSL International from 2001 to 2003.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the publisher, Editor or Editorial Board. Accordingly the publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Dermatology in practice is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2021 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 0262-5504 (Print) ISSN 2049-8446 (Online)